HUE060878T2 - Anti-transztiretin antitestek - Google Patents
Anti-transztiretin antitestekInfo
- Publication number
- HUE060878T2 HUE060878T2 HUE16702812A HUE16702812A HUE060878T2 HU E060878 T2 HUE060878 T2 HU E060878T2 HU E16702812 A HUE16702812 A HU E16702812A HU E16702812 A HUE16702812 A HU E16702812A HU E060878 T2 HUE060878 T2 HU E060878T2
- Authority
- HU
- Hungary
- Prior art keywords
- transthyretin antibodies
- transthyretin
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109002P | 2015-01-28 | 2015-01-28 | |
| US201562266556P | 2015-12-11 | 2015-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE060878T2 true HUE060878T2 (hu) | 2023-04-28 |
Family
ID=55299694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16702812A HUE060878T2 (hu) | 2015-01-28 | 2016-01-28 | Anti-transztiretin antitestek |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20160251418A1 (enExample) |
| EP (2) | EP3250592B1 (enExample) |
| JP (2) | JP6748086B2 (enExample) |
| KR (2) | KR102598180B1 (enExample) |
| CN (1) | CN107406499B (enExample) |
| AU (1) | AU2016210888C1 (enExample) |
| CA (1) | CA2974912A1 (enExample) |
| CL (2) | CL2017001924A1 (enExample) |
| CO (1) | CO2017008476A2 (enExample) |
| CU (1) | CU24480B1 (enExample) |
| DK (1) | DK3250592T3 (enExample) |
| EA (1) | EA036080B1 (enExample) |
| ES (1) | ES2934656T3 (enExample) |
| FI (1) | FI3250592T3 (enExample) |
| HR (1) | HRP20221538T1 (enExample) |
| HU (1) | HUE060878T2 (enExample) |
| IL (1) | IL253633B (enExample) |
| LT (1) | LT3250592T (enExample) |
| MX (1) | MX394170B (enExample) |
| PE (1) | PE20180217A1 (enExample) |
| PH (1) | PH12017501318B1 (enExample) |
| PL (1) | PL3250592T3 (enExample) |
| PT (1) | PT3250592T (enExample) |
| RS (1) | RS63906B1 (enExample) |
| SA (1) | SA517382002B1 (enExample) |
| SG (2) | SG11201706124VA (enExample) |
| SI (1) | SI3250592T1 (enExample) |
| TW (2) | TWI786505B (enExample) |
| UA (1) | UA122142C2 (enExample) |
| WO (1) | WO2016120810A1 (enExample) |
| ZA (1) | ZA201705663B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7076711B2 (ja) * | 2016-07-02 | 2022-05-30 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| WO2019071206A1 (en) * | 2017-10-06 | 2019-04-11 | Prothena Biosciences Limited | METHODS OF DETECTING TRANSTHYRETIN |
| MX2020003041A (es) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina. |
| MX2020005433A (es) * | 2017-11-29 | 2020-08-27 | Prothena Biosciences Ltd | Formulacion liofilizada de un anticuerpo monoclonal contra la transtirretina. |
| US20210400932A1 (en) | 2018-11-09 | 2021-12-30 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
| EP4121766A1 (en) | 2020-03-18 | 2023-01-25 | AL-S Pharma AG | Misfolded sod1 assay |
| MX2022014223A (es) | 2020-05-12 | 2023-04-14 | Neurimmune Ag | Terapia de combinacion para amiloidosis de la ttr. |
| US20230340089A1 (en) * | 2020-05-14 | 2023-10-26 | City Of Hope | Smc1a antibodies and uses thereof |
| JP2023548005A (ja) * | 2020-10-28 | 2023-11-15 | ノヴォ ノルディスク アー／エス | 抗トランスサイレチン抗体およびその使用方法 |
| CN113845593B (zh) * | 2021-10-27 | 2023-03-10 | 福州迈新生物技术开发有限公司 | 抗α-SMA蛋白单克隆抗体、细胞系及其应用 |
| JP2024544924A (ja) * | 2021-11-12 | 2024-12-05 | エーディーアールエックス， インコーポレイテッド | トランスサイレチン（ｔｔｒ）単量体結合抗体 |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| JP2026505138A (ja) * | 2022-10-19 | 2026-02-12 | アイバイオ， インク． | ケモカイン受容体８（ｃｃｒ８）抗体 |
| EP4619431A1 (en) | 2022-11-15 | 2025-09-24 | Neurimmune AG | Methods for treating or preventing transthyretin-mediated amyloidosis |
| TW202440636A (zh) * | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
| EP4713354A1 (en) | 2023-05-19 | 2026-03-25 | Neurimmune AG | Novel immunotherapy for musculoskeletal disorders and conditions |
| WO2025104243A1 (en) | 2023-11-15 | 2025-05-22 | Neurimmune Ag | Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis |
| WO2025125544A1 (en) | 2023-12-15 | 2025-06-19 | Novo Nordisk A/S | Stable liquid formulations |
| WO2025238147A1 (en) | 2024-05-15 | 2025-11-20 | Neurimmune Ag | Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| MXPA01007845A (es) | 1999-02-05 | 2004-06-22 | Samsung Electronics Co Ltd | Metodo para la recuperacion de la textura de imagenes y aparato para el mismo. |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| AU2002361886A1 (en) | 2001-12-28 | 2003-07-24 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| JP4344325B2 (ja) | 2002-11-29 | 2009-10-14 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法 |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| CA2578400C (en) | 2004-11-10 | 2014-01-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| WO2007124345A2 (en) | 2006-04-21 | 2007-11-01 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Beta-amyloid pet imaging agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| DK2099823T4 (da) | 2006-12-01 | 2022-05-09 | Seagen Inc | Målbindingsmiddelvarianter og anvendelser deraf |
| SI2126093T1 (sl) | 2007-03-02 | 2013-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Izboljšanje priprave proteinov |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| FI20115165A0 (fi) * | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Terapeuttisia ja diagnostisia menetelmiä |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| EP2953970A4 (en) * | 2013-02-08 | 2016-06-29 | Misfolding Diagnostics Inc | TRANSTYRETIN ANTIBODIES AND USES THEREOF |
| US20160168235A1 (en) * | 2013-07-19 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
| WO2019071206A1 (en) | 2017-10-06 | 2019-04-11 | Prothena Biosciences Limited | METHODS OF DETECTING TRANSTHYRETIN |
-
2016
- 2016-01-27 TW TW110100085A patent/TWI786505B/zh active
- 2016-01-27 TW TW105102535A patent/TWI718122B/zh active
- 2016-01-28 HU HUE16702812A patent/HUE060878T2/hu unknown
- 2016-01-28 CA CA2974912A patent/CA2974912A1/en active Pending
- 2016-01-28 KR KR1020177023749A patent/KR102598180B1/ko active Active
- 2016-01-28 US US15/009,662 patent/US20160251418A1/en not_active Abandoned
- 2016-01-28 SI SI201631652T patent/SI3250592T1/sl unknown
- 2016-01-28 WO PCT/IB2016/050415 patent/WO2016120810A1/en not_active Ceased
- 2016-01-28 EP EP16702812.5A patent/EP3250592B1/en active Active
- 2016-01-28 CN CN201680010882.7A patent/CN107406499B/zh active Active
- 2016-01-28 UA UAA201708667A patent/UA122142C2/uk unknown
- 2016-01-28 EP EP22195219.5A patent/EP4134379A1/en active Pending
- 2016-01-28 MX MX2017009806A patent/MX394170B/es unknown
- 2016-01-28 PL PL16702812.5T patent/PL3250592T3/pl unknown
- 2016-01-28 LT LTEPPCT/IB2016/050415T patent/LT3250592T/lt unknown
- 2016-01-28 DK DK16702812.5T patent/DK3250592T3/da active
- 2016-01-28 AU AU2016210888A patent/AU2016210888C1/en active Active
- 2016-01-28 HR HRP20221538TT patent/HRP20221538T1/hr unknown
- 2016-01-28 ES ES16702812T patent/ES2934656T3/es active Active
- 2016-01-28 KR KR1020237037602A patent/KR102677203B1/ko active Active
- 2016-01-28 SG SG11201706124VA patent/SG11201706124VA/en unknown
- 2016-01-28 EA EA201791712A patent/EA036080B1/ru unknown
- 2016-01-28 CU CU2017000097A patent/CU24480B1/es unknown
- 2016-01-28 SG SG10202101763VA patent/SG10202101763VA/en unknown
- 2016-01-28 PE PE2017001287A patent/PE20180217A1/es unknown
- 2016-01-28 JP JP2017539650A patent/JP6748086B2/ja active Active
- 2016-01-28 PT PT167028125T patent/PT3250592T/pt unknown
- 2016-01-28 FI FIEP16702812.5T patent/FI3250592T3/fi active
- 2016-01-28 RS RS20221170A patent/RS63906B1/sr unknown
-
2017
- 2017-07-20 PH PH12017501318A patent/PH12017501318B1/en unknown
- 2017-07-24 IL IL253633A patent/IL253633B/en active IP Right Grant
- 2017-07-27 SA SA517382002A patent/SA517382002B1/ar unknown
- 2017-07-27 CL CL2017001924A patent/CL2017001924A1/es unknown
- 2017-08-21 ZA ZA2017/05663A patent/ZA201705663B/en unknown
- 2017-08-22 CO CONC2017/0008476A patent/CO2017008476A2/es unknown
-
2020
- 2020-08-06 JP JP2020133642A patent/JP7028923B2/ja active Active
-
2022
- 2022-11-02 CL CL2022003027A patent/CL2022003027A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| PL3606954T3 (pl) | Przeciwciała anty-LAG3 | |
| IL251963A0 (en) | Anti-pd-1 antibodies | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| EP3356420C0 (en) | MULTI-SPECIFIC ANTIBODIES | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| IL256099A (en) | Antibody | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| PL3556777T3 (pl) | Konstrukty przeciwciał wieloswoistych | |
| EP3319983C0 (en) | TAU LINKING ANTIBODIES | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| IL291164A (en) | Anti-nme antibody | |
| PL3215530T3 (pl) | Ulepszone przeciwciała anty-il-6 | |
| LT3092003T (lt) | Naujas anti-netrino-1 antikūnas | |
| IL257368A (en) | Antibody | |
| DK3484921T3 (da) | Anti-IL-22R antistoffer | |
| DK3452515T3 (da) | Her-2-bindende antistoffer |